
Health Care Delivery
Latest News
Advertisement
CME Content
Advertisement

























Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
5 Things to Know About the Oral GLP-1 Era
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention
5










